Exhibit 99.1

Interleukin Genetics Announces Changes in Executive Management; Move Signals
Shift to Commercial Priorities

    WALTHAM, Mass.--(BUSINESS WIRE)--March 31, 2006--Interleukin
Genetics, Inc. (AMEX:ILI) today announced changes in its executive
management team intended to accelerate development and
commercialization of products utilizing its genetic based intellectual
property.
    Kenneth S. Kornman, DDS, Ph.D., founder, President and Chief
Scientific Officer of the Company, will assume the additional role of
Chief Executive Officer, effective immediately. Dr. Kornman will
continue to oversee the relationship with the Company's primary
strategic partner, Alticor, to facilitate the launch of genetic tests
globally.
    The Company also announced the addition of Gregg Mayer as Chief
Business Officer. Mr. Mayer has extensive business strategy, marketing
and product commercialization experience with Abbott Diagnostics,
Chiron Diagnostics, and most recently at EPIX Pharmaceuticals where he
was Vice President of Strategic Marketing and Communications. Mr.
Mayer will lead the efforts to build product and testing revenues
beyond the current commercialization partnership with Alticor.
    Philip R. Reilly, MD, JD will continue in his position as Chairman
of the Board of Directors but has stepped down as CEO. This will allow
Dr. Reilly to focus exclusively on growing Interleukin's genetic
testing business. He has signed a two-year part-time employment
agreement with the Company and will develop genetic testing
opportunities with executive management while continuing to provide
valuable strategic insight to the Board.
    Dr. Ramon Mohanlal, who joined the Company last year as Chief
Medical officer, will continue to lead the business strategy and
product development in therapeutics and pharmacogenetics.
    "We are very pleased to announce these important changes to our
executive team," said Dr. Reilly. "As we focus the Company's
priorities on providing genetic testing services and developing new
therapeutic and preventive products, we are reshaping the management
responsibilities to support these strategic business objectives, " Dr.
Reilly added. "Having served the Company as CEO for six years, I
believe that I can best serve the Company and its shareholders by
working to maximize the success and expansion of our genetic testing
business. In addition, I look forward to expanding and supporting the
application of the science and technology of genetic testing, long a
special interest of mine, and a key to the future growth of
Interleukin Genetics in the near term."
    Dr. Kornman, who founded the Company more than a decade ago, is
deeply committed to making Interleukin Genetics a leader in the new
field of personalized health care. Two years ago the Company began
building a genetic testing lab. "It is certainly gratifying to see the
genetic testing laboratory processing hundreds of tests daily derived
from our intellectual property," said Dr. Kornman. "I am especially
excited about working with our strategic partner, Alticor, as we
expand this business globally. "As we look to grow our Company through
new channels," added Dr. Kornman, "Gregg Mayer, who has had a long,
successful career in both the medical diagnostics and biotechnology
sectors, brings the partnering expertise Interleukin needs. In
addition to his deep experience in commercializing diagnostic
products, Gregg has the skills to help drive other lines of business
that we plan to pursue."

    About Interleukin

    Interleukin Genetics is a biotechnology company focused on
developing personalized health products. The company uses functional
genomics to help in the development of risk assessment tests,
pharmacogenetic tests, nutritional and therapeutic products based on
the genetic variations in people. Interleukin's current programs focus
on cardiovascular disease, osteoporosis, periodontal disease and
weight management. Interleukin expects that these programs will lead
to products that will personalize the selection of nutritional and
therapeutic products and enable the managed care industry to improve
patient care and better allocate resources. For more information about
Interleukin and its ongoing programs, please visit
http://www.ilgenetics.com.

    Certain statements contained herein are "forward-looking"
statements including statements regarding our ability to develop
diagnostic, personalized nutritional and therapeutic products to
prevent or treat diseases of inflammation and other genetic
variations, our ability to screen nutritional compounds for their
effects on inflammatory responses and other genetic variations, given
specific genetic patterns and our ability to make progress in
advancing our core technologies. Because such statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from those expressed
or implied by such forward-looking statements include, but are not
limited to, our ability to develop diagnostic, personalized
nutritional and therapeutic products to prevent or treat diseases of
inflammation and other genetic variations, our ability to screen
nutritional compounds for their effects on inflammatory responses and
other genetic variations, given specific genetic patterns, our ability
to obtain and maintain CLIA certification of our CLIA registered
testing laboratory, our ability to complete all of our key milestones
with regard to Alticor programs, our ability to make progress in
advancing our core technologies and our ability to launch new
commercial products and those risks and uncertainties described in our
annual report on Form 10-K for the year ended December 31, 2005 filed
with the Securities and Exchange Commission. We disclaim any
obligation or intention to update these forward-looking statements.

    CONTACT: For Interleukin Genetics:
             Kenneth S. Kornman, 781-398-0700